---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-006716"
form_type: "8-K"
ticker: "ODYY"
cik: "0001626644"
company_name: "Odyssey Health, Inc."
filed_at: "2022-10-03T23:59:59+00:00"
generated_at: "2026-06-23T05:58:49.311386+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Odyssey Health dissolves sports advisory board, provides concussion drug update: Phase I complete, Phase II planned

## Summary
- Dissolved sports advisory board to eliminate distraction and maintain focus on drug development.
- Phase I human trial completed; drug proven safe and well tolerated.
- Company plans to initiate Phase II trial to evaluate efficacy and safety in concussed patients.
- Company states it has never received government funding; drug development funded by accredited investors.
- Intellectual property and rights to the drug purchased on March 1, 2021 from a third party.

## SEC filing metadata
- accession: 0001683168-22-006716
- form_type: 8-K
- ticker: ODYY
- cik: 0001626644
- company_name: Odyssey Health, Inc.
- filed_at: 2022-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626644/000168316822006716/0001683168-22-006716-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626644/000168316822006716/odyssey_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-006716
- JSON: https://secwatch.observer/filing/0001683168-22-006716.json
- Plain text: https://secwatch.observer/filing/0001683168-22-006716.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.